Focus Partners Wealth

Position in EXEL — Exelixis, Inc.

CIK 1542153 ST LOUIS, MO

Position in EXEL

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$4,622,512

-$92,456 QoQ

Shares Held

107,776

+0.2% QoQ

Ownership

0.043%

of shares outstanding

% of Portfolio

0.01%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Dec 2023

10 quarters on record

Voting authority Sole 3.583358076009501.ToString("F0")% Shared 0.ToString("F0")% None 96.4166419239905.ToString("F0")%

Healthcare · as of Mar 31, 2026

Focus Partners Wealth holds $172,241,737 across 69 Biotechnology names. EXEL ranks #8 (2.7% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	131,435	$58,690,984
2	CELC	Celcuity Inc.	233,390	$26,639,134
3	REGN	Regeneron Pharmaceuticals, Inc.	16,441	$12,702,974
4	IONS	Ionis Pharmaceuticals Inc	165,544	$12,430,698
5	HALO	Halozyme Therapeutics, Inc.	169,286	$10,940,954
6	INCY	Incyte Corp	116,075	$10,924,979
7	RPRX	Royalty Pharma plc	116,250	$5,576,512
8	EXEL	Exelixis, Inc. This page	107,776	$4,622,512

10 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$4,622,512	107,776	+0.2%	Shares	Sole	2026-05-15
2025-12-31	$4,714,968	107,574	-25.7%	Shares	Sole	2026-02-13
2025-09-30	$5,980,322	144,802	+263.5%	Shares	Sole	2025-11-14
2025-06-30	$1,756,014	39,837	+3.6%	Shares	Sole	2025-08-14
2025-03-31	$1,419,869	38,458	+82.5%	Shares	Sole	2025-05-20
2024-12-31	$701,797	21,075	-13.4%	Shares	Sole	2025-05-29
2024-09-30	$631,415	24,332	+0.5%	Shares	Sole	2024-11-14
2024-06-30	$544,268	24,222	+1.0%	Shares	Sole	2024-08-15
2024-03-31	$569,306	23,991	+31.2%	Shares	Sole	2024-05-16
2023-12-31	$438,777	18,290	—	Shares	Sole	2024-02-15
No filing history on record for this holder in this stock.